Exploring synergy of combined BRAF-targeted therapy & immunotherapy for melanoma

探索联合 BRAF 靶向治疗的协同作用

• 批准号: 8926888
• 负责人: Jennifer A. Wargo
• 金额: $ 14.26万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-03 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8926888
• 关键词: Address; Advisory Committees; Antigens; Award; BRAF gene; Behavior; Biopsy; Cell Line; Complex; Data; Development; Differentiation Antigens; Disease; Down-Regulation; Funding; Goals; Hand; Immune; Immune response; Immunologics; Immunosuppressive Agents; Immunotherapy; In Vitro; Incidence; Knowledge; Lead; Learning; Life; MAP Kinase Gene; MEKs; Malignant Neoplasms; Melanoma Cell; Mentors; Metastatic Melanoma; Mission; Modeling; Molecular; Mus; Mutate; Mutation; Nature; Oncogenic; Operative Surgical Procedures; Organism; Pathway interactions; Patients; Physicians; Production; Public Health; Publications; Reagent; Reporting; Repression; Research; Research Personnel; Resources; Scientist; Signal Pathway; Signal Transduction; Staging; T-Lymphocyte; Techniques; Testing; Therapeutic; Training Activity; Work; World Health; base; burden of illness; career development; cytokine; disability; genetic immunotherapy; improved; in vivo; in vivo Model; inhibitor/antagonist; innovation; insight; melanocyte; melanoma; mutant; novel; novel therapeutic intervention; novel therapeutics; response; targeted treatment; treatment strategy; tumor

DESCRIPTION (provided by applicant): Targeted therapy against the BRAF/MAPK pathway is an exciting new therapeutic approach for the treatment of melanoma. However despite high initial response rates, duration of response is limited. This may be due to redundancy and signaling through different oncogenic pathways, though preliminary evidence suggests that oncogenic BRAF (present in 60% of melanomas) may contribute to immune escape through suppression of melanocyte differentiation antigens and increased production of immunosuppressive cytokines. There is a fundamental gap in the understanding of how oncogenic BRAF contributes to immune escape in melanoma, and a better understanding of this dynamic interplay may lead to advances in treatment. The long term goal of this proposal is to better understand the downstream signaling responses and immune responses to oncogenic BRAF and BRAF inhibition in melanoma. The objective in this particular application is to study these responses in vitro and in an in vivo model of BRAF-mutant melanoma, as well as in patients with metastatic melanoma being treated with BRAF inhibitors. The central hypothesis is that oncogenic BRAF contributes to immune escape in melanoma through down-regulation of melanocyte differentiation antigens and increased production of immunosuppressive cytokines. This hypothesis has been formulated based on preliminary data produced by the candidate under the guidance of her mentor. The rationale for the proposed research is that combination of targeted BRAF inhibition and immunotherapy will lead to improved therapeutic strategies for the treatment of melanoma, which may ultimately be extended to other BRAF-mutant cancers. This hypothesis will be tested by pursuing two specific aims: 1) Examining downstream signaling responses in BRAF mutant melanoma treated with MAPK pathway inhibition or a selective inhibitor of BRAFV600E in vitro & in vivo; and 2) Exploring the mechanism of melanoma immune response to MAPK / BRAF inhibition in vitro & in vivo. Under these aims, reagents and resources already on hand will be used to interrogate signaling pathways and immune responses using established techniques feasible in the applicant's hands. The approach is innovative, because it connects the fields of melanoma genetics and immunotherapy with the intent of providing new therapeutic options through a better understanding of the complex interplay between oncogenic mutations and immune escape. The proposed research is significant, because it is expected to result in new therapeutic strategies for the treatment of BRAF-mutant melanoma with the opportunity to study and apply what we learn to the treatment of other BRAF-mutant cancers.

描述（由申请方提供）：针对BRAF/MAPK通路的靶向治疗是治疗黑色素瘤的令人兴奋的新治疗方法。然而，尽管初始响应率很高，响应的持续时间是有限的。这可能是由于冗余和通过不同致癌途径的信号传导，尽管初步证据表明致癌BRAF（存在于60%的黑素瘤中）可能通过抑制黑素细胞分化抗原和增加免疫抑制细胞因子的产生而有助于免疫逃逸。在理解致癌BRAF如何有助于黑色素瘤的免疫逃逸方面存在根本性的差距，更好地理解这种动态相互作用可能会导致治疗的进步。该提案的长期目标是更好地理解下游信号传导应答和对黑色素瘤中致癌BRAF和BRAF抑制的免疫应答。本特定申请的目的是在BRAF突变型黑素瘤的体外和体内模型中以及在用BRAF抑制剂治疗的转移性黑素瘤患者中研究这些应答。核心假设是致癌BRAF通过下调黑素细胞分化抗原和增加免疫抑制细胞因子的产生而促进黑色素瘤中的免疫逃逸。这一假设是根据候选人在其导师的指导下产生的初步数据制定的。拟议研究的基本原理是靶向BRAF抑制和免疫疗法的组合将导致改善治疗黑色素瘤的治疗策略，最终可能扩展到其他BRAF突变癌症。该假设将通过追求两个具体目标来测试：1）在体外和体内检查用MAPK通路抑制剂或BRAFV 600 E的选择性抑制剂处理的BRAF突变黑素瘤中的下游信号传导应答;和2）在体外和体内探索黑素瘤对MAPK / BRAF抑制的免疫应答的机制。在这些目标下，现有的试剂和资源将用于使用申请人手中可行的既定技术来询问信号通路和免疫应答。该方法具有创新性，因为它将黑色素瘤遗传学和免疫治疗领域联系起来，旨在通过更好地了解致癌突变和免疫逃逸之间复杂的相互作用来提供新的治疗选择。这项拟议的研究意义重大，因为它有望为治疗BRAF突变型黑色素瘤提供新的治疗策略，并有机会研究和应用我们所学到的治疗其他BRAF突变型癌症。